Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus
Inventors
Faulkner, Mark C. • Miller, Donald W.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11826334-B2
Publication Date
2023-11-28
Expiration Date
Abstract
Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses.
Core Innovation
The invention relates to antiviral therapeutic compounds and compositions for preventing and/or treating coronavirus in a patient in need thereof. The disclosed antiviral therapeutic compounds include creatine cyclohexyl ester, creatine isopentyl ester, betaine cyclopentyl ester, and combinations thereof.
A further embodiment provides a composition that includes an antiviral therapeutic compound selected from creatine cyclohexyl ester, creatine isopentyl ester, betaine cyclopentyl ester, and combinations thereof, together with the anti-inflammatory agent ethyl (α-guanido-methyl) ethanoate. The antiviral therapeutic compound is present in the composition in an amount of about 50 percent or greater by weight, and the composition is administered orally or intravenously to the patient.
The invention is directed to an immunomodulatory outcome in the context of coronavirus treatment. The disclosed methods include administering a treatment that decreases expression of proinflammatory cytokines, including IL-6, IL-1β, TNF, CXCL1, and CXCL2, and increases interferon gamma release from T cells.
Claims Coverage
The provided independent claims cover methods for treating coronavirus by administering an effective amount of a composition containing specific antiviral therapeutic compounds, with route options and, in one claim family, inclusion of an anti-inflammatory agent plus immunomodulatory functional outcomes. Across the independent claims, the inventive features number at least four.
Coronavirus treatment by creatine cyclohexyl ester and/or creatine isopentyl ester
A method of treating coronavirus in a patient in need thereof by administering an effective amount of a composition comprising at least one antiviral therapeutic compound selected from creatine cyclohexyl ester, creatine isopentyl ester, and combinations thereof.
Coronavirus treatment by creatine cyclohexyl ester, creatine isopentyl ester, and betaine cyclopentyl ester
A method of treating coronavirus in a patient in need thereof by administering an effective amount of a composition comprising at least one antiviral therapeutic compound selected from creatine cyclohexyl ester, creatine isopentyl ester, betaine cyclopentyl ester, and combinations thereof.
Coronavirus treatment using antiviral creatine/betaine esters plus ethyl (α-guanido-methyl) ethanoate
A method of treating coronavirus in a patient in need thereof by administering an effective amount of a composition comprising at least one antiviral therapeutic compound selected from creatine cyclohexyl ester, creatine isopentyl ester, betaine cyclopentyl ester, and combinations thereof, and at least one anti-inflammatory agent being ethyl (α-guanido-methyl) ethanoate, with the antiviral therapeutic compound present in the composition in an amount of about 50 percent or greater by weight of the composition.
Immunomodulatory functional effects on proinflammatory cytokines and interferon gamma release
Administering includes decreasing expression of proinflammatory cytokines and increasing interferon gamma release in the patient.
The independent claims are directed to treating coronavirus by administering effective amounts of compositions containing creatine cyclohexyl ester and/or creatine isopentyl ester, with one claim family expanding to betaine cyclopentyl ester and, in one independent claim, combining the antiviral therapeutic compound(s) with ethyl (α-guanido-methyl) ethanoate at a weight-constrained level of the antiviral component. The claim set further ties treatment to oral or intravenous administration and to functional immunological outcomes involving decreased proinflammatory cytokine expression and increased interferon gamma release.
Stated Advantages
Decreases expression of proinflammatory cytokines.
Increases interferon gamma release.
Documented Applications
Preventing and/or treating coronavirus in a patient in need thereof.
Treating coronavirus using antiviral therapeutic compounds and compositions; immunomodulatory effects include decreased proinflammatory cytokine expression and increased interferon gamma release.
Treating coronavirus using antiviral therapeutic compounds with an anti-inflammatory agent ethyl (α-guanido-methyl) ethanoate.
Interested in licensing this patent?